Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Venclexta (venetoclax)
Pharma
Lilly oncology chief ‘blown away’ by new Jaypirca CLL data
The addition of Jaypirca to a fixed-duration regimen with venetoclax and rituximab improved PFS by 45.3% in previously treated CLL.
Angus Liu
Jun 15, 2026 8:25am
BeOne's Venclexta challenger Beqalzi nets FDA approval
May 13, 2026 4:45pm
Lilly touts Jaypirca fixed-duration win in ‘ambitious’ CLL trial
Apr 13, 2026 10:16am
AZ nabs Calquence fixed-duration nod to counter BeOne’s CLL push
Feb 20, 2026 11:05am
AbbVie, Roche fail again in label expansion bid for Venclexta
Jun 16, 2025 4:23pm
AstraZeneca trumpets new Calquence combos in CLL
Jul 29, 2024 10:25am
